Reflow Medical Reports Six-Month Results from DEEPER CORONARY Study of Spur® Elute Stent

Reflow Medical Reports Six-Month Results from DEEPER CORONARY Study of Spur® Elute Stent

Reflow Medical, Inc., a leading developer of innovative devices for treating complex cardiovascular disease, announces the presentation of the first six-month clinical results from the DEEPER CORONARY study at EuroPCR 2026 in Paris, France. The study evaluates the investigational coronary Spur® Elute Sirolimus-Eluting Retrievable Stent System for coronary in-stent restenosis (ISR).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520334491/en/

The data was presented by Scott Harding, MD, Director of the Cardiology Research Group at Wellington Hospital, Wellington, New Zealand, and principal investigator for the DEEPER CORONARY trial.

DEEPER CORONARY is a first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute System as a primary treatment for coronary ISR. Six-month study results showed 100% freedom from MACE and 100% freedom from all-cause mortality among nine treated subjects. Improvement in CCS angina class was observed in all patients, with a median improvement of three classes.